In patients with urothelial carcinoma (UC), the relationship between PD-L1 and PD-1 leads to the inaction of T cells across the microenvironment and the evasion of host immune response. A hospital-based observational study from Anushweta Singh, MD, and colleagues published in Cureus investigated the role of PD-L1 in patients with UC and analyzed its expression using histomorphological parameters. ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
The new recommendations included changes to neoadjuvant and adjuvant chemotherapy and radical cystectomy.
Results from the NIAGARA trial show significant survival benefits with durvalumab for muscle invasive bladder cancer.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC.
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Of the 26 patients with pathological assessment upon safety visit, all reached pCR, while none received cystectomy.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
